AcuCort

The study will run concurrently with the Nordic market launch. In the study, allergy patients are assigned the company's oral film Zeqmelit® for use when the need for treatment for acute allergic reactions arises.

The goal of the study, which is an open-label non-randomized low-intervention study, is to obtain valuable data on the use of Zeqmelit® from patients who have previously been prescribed corticosteroids in tablet form for self-treatment during acute allergic reactions.

"We are reaching a very important milestone now as the first patient is using Zeqmelit. The initiation of the study supports the ongoing commercialization efforts and the upcoming market launch in the Nordic region," says Jonas Jönmark, CEO of AcuCort.

The study includes about 50 allergy patients who will be added continuously over the next six months.

"We look forward to publishing the study results at the end of the year. We believe it will be an important part of the marketing of Zeqmelit® as we will be able to communicate real experiences from patients and doctors," says Jonas Jönmark."